What did @dusansajicmd actually say?
The creator disclosed a serious personal health event: retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, put them in the hospital for three days with necrotizing pancreatitis. They described it plainly: "parts of it weren't getting blood flow and ended up dying off." They also claimed retatrutide appears to preserve muscle and may make muscle gain easier, before closing with a general warning to report symptoms to a provider immediately.
This is a short video doing a few things at once. It is a personal disclosure, a basic pharmacology explainer, and a safety warning. That combination is worth unpacking carefully, because not all three parts hold up equally well to scrutiny.
Does the science back this up?
The pancreatitis risk is real and documented. The muscle-preservation claims are plausible but far from settled. GLP-1 receptor agonists as a class carry an FDA-labeled warning for pancreatitis risk, and retatrutide is no exception.
A 2023 phase 2 trial of retatrutide published in the New England Journal of Medicine (Jastreboff et al., 2023) showed significant weight loss across dose groups but also reported gastrointestinal adverse events as the most common side effects. Pancreatitis cases were low in frequency but present. The mechanism is not fully understood, but leading hypotheses involve GLP-1-mediated effects on pancreatic enzyme secretion and ductal pressure.
On muscle preservation, GLP-1 agonists have been associated with lean mass loss alongside fat loss in several trials. Retatrutide's glucagon receptor agonism may theoretically support metabolic rate in a way that partially offsets lean mass reduction, but no peer-reviewed human trial has yet demonstrated that retatrutide makes it easier to gain muscle. That claim is speculative at this stage of research.
What did they get wrong (or right)?
They got the pancreatitis risk right, and they deserve credit for disclosing it publicly rather than downplaying it. First-person adverse event reporting from a clinician carries real informational value, even if it is anecdotal.
Where they overstep is the muscle claim. Saying retatrutide is "potentially making it easier to gain muscle" is not supported by current clinical evidence. There is preclinical and mechanistic interest in the glucagon receptor component affecting body composition, and some patients in trials showed favorable lean mass ratios, but "easier to gain muscle" is a stretch that will land in many viewers' brains as a selling point rather than a hypothesis.
They also describe retatrutide as "one of the GLP-1 agonists," which is technically correct but undersells the distinction. Triple agonism means a meaningfully different pharmacological profile than semaglutide or tirzepatide, and that distinction matters for both efficacy and risk discussions. Grouping them loosely can give viewers false confidence that side effect profiles are interchangeable.
What should you actually know?
Necrotizing pancreatitis is not a minor side effect. It carries a mortality rate estimated between 15 and 35 percent in severe cases, according to a review by Boxhoorn et al. (2020, The Lancet). Most cases of GLP-1-associated pancreatitis are acute and interstitial, meaning the necrotic form the creator experienced sits at the severe end of the spectrum.
Retatrutide is not FDA-approved as of mid-2025. It is being studied under Eli Lilly's pipeline and is available only through clinical trials or, in some markets, through compounding channels that operate in a regulatory gray zone. Anyone accessing this compound outside a clinical trial should understand they are using an investigational agent with incomplete long-term safety data.
The creator's closing advice, to report symptoms to your provider immediately, is the right call. Early symptoms of pancreatitis include severe upper abdominal pain radiating to the back, nausea, and vomiting. Those symptoms warrant emergency evaluation, not a wait-and-see approach.
- Do not assume GLP-1 class safety data from semaglutide or tirzepatide fully applies to retatrutide.
- Muscle gain claims for retatrutide are not backed by completed human clinical trials.
- Pancreatitis, including the necrotizing form, is a documented risk across the GLP-1 agonist class.
- Anyone using retatrutide should have a supervising clinician who knows they are on it.